Connect Biopharma Holdings Limited (CNTB)
NGM · Healthcare · Biotechnology
$2.12
+0.95%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$133.5M
Shares Outstanding
63.0M
P/S (TTM)
573x
Exchange
NGM
Currency
USD
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 48K | 16K | 0.00 | 169K |
| Operating Income | -13.4M | -17.7M | -15.5M | -19.6M |
| Net Income | -12.9M | -17.2M | -15.1M | -19.4M |
| Diluted EPS | $-0.23 | $-0.31 | $-0.27 | $-0.34 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 26.0M | 64K |
| Operating Income | -116.5M | -69.1M | -22.5M | -58.1M |
| Net Income | -118.1M | -62.1M | -15.6M | -55.5M |
| Diluted EPS | $-2.10 | $-1.13 | $-0.28 | $-1.00 |